Drug Formulation Market 2024 : Industry Analysis, Trends, Segmentation, Regional Overview And Forecast 2033

The Drug Formulation by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Drug Formulation Market:

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

According to The Business Research Company’s Drug Formulation, The drug formulation market size has grown strongly in recent years. It will grow from $1780.87 billion in 2023 to $1931.05 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to biopharmaceutical innovation, patient-centric drug development, personalized medicine, regulatory support for orphan drugs, increased r&d investmen.

The drug formulation market size is expected to see strong growth in the next few years. It will grow to $2682.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to advancements in 3d printing, focus on pediatric formulations, biological drug delivery systems, green chemistry in formulation, integration of artificial intelligence (ai). Major trends in the forecast period include biopharmaceuticals and biologics dominance, advanced drug delivery systems, personalized medicine and individualized formulations, incorporation of nanotechnology, lifecycle management and reformulation strategies.

The rising prevalence of chronic diseases is expected to propel the growth of the drug formulation market going forward. Chronic diseases can be defined as conditions that last 1 year or more and require ongoing medical attention, limit activities of daily living, or both. Drug formulation has the potential to reduce the prevalence of chronic illnesses where multiple drug delivery methods are utilized to optimize therapeutic efficacy while minimizing adverse effects by influencing medication absorption, distribution, metabolism, and excretion. For instance, in September 2022, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, in 2023, in the United States, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.52 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity would rise by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. Therefore, the rising prevalence of chronic diseases is driving the growth of the drug formulation market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9900&type=smp

The drug formulation market covered in this report is segmented –

1) By Dosage Form: Oral formulations, Parenteral Formulations, Topical Formulations, Inhalation Formulations

2) By Formulation: Tablets, Capsules, Injectable, Sprays, Suspensions, Powders, Other Formulations

3) By Therapy Area: Cardiovascular Diseases (CVDs), Pain, Diabetes, Cancer, Respiratory Diseases, Other Diseases

4) By End-User: Big Pharma, Small And Medium Pharma, Biotech Companies

Technological advancements are a key trend gaining popularity in the drug formulation market. Major players operating in the drug formulation market are concentrating their efforts on introducing new and advanced technologies to strengthen their position in the market. For instance, in June 2022, Merck & Co., Inc., a US-based pharmaceutical company, launched Merck Digital Sciences Studio (MDSS) to make it possible to create innovative technologies for drug research and development. Merck uses Azure Clouds robust computing and Merck’s discovery and clinical experts to collaboratively accelerate and take over novel and innovative digital technologies. MDSS is a collaboration between Merck and the New Jersey Innovation Institute (NJII), a US-based company owned by the New Jersey Institute of Technology. The Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures have all invested in the project. Microsoft will provide start-up companies with technology support.

The drug formulation market report table of contents includes: